Clinical trial · Interventional
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma: A Phase II, Multi-center, Open-label Study
NCT02328261CI-TRIAL-00016489unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Icotinib | Drug | Icotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Icotinib
- description
- Icotinib (125 mg tablet) is orally administered three times daily
- interventionNames
- Drug: Icotinib
Primary outcomes (1)
- measure
- Disease control rate(DCR)
- timeFrame
- At least 8 weeks
Secondary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- At least 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed advanced NPC * Patients must be platinum-resistant defined as recurrence or progression of disease \<6 months since previous treatment with a platinum based treatment regimen. * Measurable disease per RECIST * Adequate organ and marrow function * Capable of understanding and complying with the protocol, and written informed consent Exclusion Criteria: * Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR * Patients must not be receiving any other investigational agents * Other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), or active uncontrolled infection * Women who are pregnant or breast-feeding
References
Publications (0)
Data not yet available
No reference posted for this study.